Genetic deficiency or pharmacological inhibition of miR-33 protects from kidney fibrosis

JCI Insight, Journal Year: 2019, Volume and Issue: 4(22)

Published: Oct. 15, 2019

Previous work has reported the important links between cellular bioenergetics and development of chronic kidney disease, highlighting potential for targeting metabolic functions to regulate disease progression. More recently, it been shown that alterations in fatty acid oxidation (FAO) can have an impact on progression disease. In this work, we demonstrate loss miR-33, regulator lipid metabolism, partially prevent repression FAO fibrotic kidneys reduce accumulation. These changes were associated with a dramatic reduction extent fibrosis induced 2 mouse models effects not related circulating leukocytes because bone marrow transplants from miR-33–deficient animals did similar Most important, targeted delivery miR-33 peptide nucleic inhibitors other acidic microenvironments was accomplished using pH low insertion peptides as carrier. This effective at both increasing expression factors involved reducing fibrosis. Together, these findings suggest may be attractive therapeutic target treatment

Language: Английский

---

Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers

Disease Markers, Journal Year: 2020, Volume and Issue: 2020, P. 1 - 16

Published: Aug. 27, 2020

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic worldwide in part due to concomitant obesity pandemic and insulin resistance (IR). It increasingly becoming evident that NAFLD a affecting numerous extrahepatic vital organs regulatory pathways. The molecular mechanisms underlying nonalcoholic steatosis formation are poorly understood, little information available on pathways responsible for progressive hepatocellular damage follows lipid accumulation. Recently, much research has focused identification of epigenetic modifications contribute pathogenesis. Noncoding RNAs (ncRNAs) one such factors could be implicated development progression. In this review, we summarize current knowledge genetic potentially disease. Particular emphasis will put contribution microRNAs (miRNAs), long noncoding (lncRNAs), circular (circRNAs) pathophysiology as well their potential use therapeutic targets or markers prediction progression

Language: Английский

---

Effects of miR-33 Deficiency on Metabolic and Cardiovascular Diseases: Implications for Therapeutic Intervention

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(13), P. 10777 - 10777

Published: June 28, 2023

MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally inhibit gene expression. These molecules involved in several biological conditions such as inflammation, cell growth and proliferation, regulation of energy metabolism. In the context metabolic cardiovascular diseases, miR-33 is particular interest it has been implicated lipid glucose This miRNA located introns harboured genes encoding sterol regulatory element-binding protein (SREBP)-1 SREBP-2, which key transcription factors biosynthesis cholesterol efflux. review outlines role a range pathologies, dyslipidaemia, nonalcoholic fatty liver disease (NAFLD), obesity, diabetes, atherosclerosis, abdominal aortic aneurysm (AAA), provides discussion about effectiveness deficiency possible therapeutic strategy to prevent development these diseases.

Language: Английский

---

MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy

Trends in Pharmacological Sciences, Journal Year: 2018, Volume and Issue: 39(11), P. 967 - 981

Published: Sept. 21, 2018

Language: Английский

---

Elucidating the contributory role of microRNA to cardiovascular diseases (a review)

Vascular Pharmacology, Journal Year: 2018, Volume and Issue: 114, P. 31 - 48

Published: Oct. 31, 2018

Cardiovascular diseases encompassing atherosclerosis, aortic aneurysms, restenosis, and pulmonary arterial hypertension, remain the leading cause of morbidity mortality worldwide. In response to a range stimuli, dynamic interplay between biochemical biomechanical mechanisms affect behaviour function multiple cell types, driving development progression cardiovascular diseases. Accumulating evidence has highlighted microRNAs (miRs) as significant regulators micro-managers key cellular molecular pathophysiological processes involved in predominant diseases, including mitosis, motility viability, lipid metabolism, generation inflammatory mediators, dysregulated proteolysis. Human pathological clinical studies have aimed identify select microRNA which may serve biomarkers disease their progression, are discussed within this review. addition, I provide comprehensive coverage vivo investigations elucidating modulation distinct on pathophysiology abdominal hypertension. Collectively, animal begun unravel complex often diverse effects targets impart during revealed promising therapeutic strategies through be applied clinically.

Language: Английский

---